Malopolskie Centrum Kliniczne

Cracow 32 trials 10 recruiting

32 Registered trials

10 Currently recruiting

Organisation

Malopolskie Centrum Kliniczne

Location

Cracow, Poland

Identifier

ORG-100043201

Address

Ul. Balicka 12a/5b, 30-149, Poland

Departments

-
#7814: Rheumatology
CWBK
MCK
N/A
NA
Nie dotyczy

Clinical trials at this site (32)

Search interface

A study to evaluate the long-term safety, tolerability, and efficacy of subcutaneous sonelokimab in participants with psoriatic arthritis (P… Pending

2025-522471-28-00 psoriatic arthritis (PsA) 5
A Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid Arthritis Recruiting

2025-520721-21-00 Rheumatoid Arthritis 4 2025-10-20
A Phase 1b, Open-Label Study of CLN-978 for the Treatment of Active, Moderate to Severe Sjogren’s Disease Recruiting

2025-521462-96-00 Sjogren's Disease 3 2025-08-05
A Phase I, Open-Label Study of CLN-978 in Patients with Treatment-Refractory Rheumatoid Arthritis (RA) Recruiting

2024-519114-31-00 Treatment-Refractory Rheumatoid Arthritis 3 2025-05-15
A study to find how well Dazodalibep works and how safe it is in participants with Sjôgren`s Syndrome Recruiting

2023-503904-10-00 Sjögren’s Syndrome With Moderate-to-severe Systemic Dis 5 2024-06-07
C0251006 - A PHASE 3, MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF-06823859 IN … Recruiting

2022-502739-20-00 Active Idiopathic Inflammatory Myopathies (Including De 5 2023-11-16
A Phase 1b open label pilot study of CLN-978 for the treatment of moderate to severe systemic lupus erythematosus (SLE) Recruiting

2024-518780-36-00 Systemic Lupus Erythematosus 3 2025-12-10
A study to find how well Dazodalibep works and how safe it is in participants with Sjôgren`s Syndrome Recruiting

2024-517513-32-00 Sjögren’s Syndrome 5 2025-05-16
A study to investigate the efficacy and safety of subcutaneous sonelokimab versus placebo and risankizumab (active reference arm) in partici… Recruiting

2024-516219-25-00 psoriatic arthritis 5 2025-03-25
An open-label extension study with dazukibart for participants with idiopathic inflammatory myopathies (including DM or PM) who have complet… Recruiting

2024-514648-10-00 Idiopathic Inflammatory Myopathy (including dermatomyos 5 2025-03-14
Study of Targeted Therapies for the Treatment of Adult Participants with Moderate to Severe Crohn’s Disease Recruiting

2024-513009-30-00 Moderate to Severe Crohn’s Disease 4 2024-11-21
A study to find if tibulizumab works and how safe it is in participants with systemic sclerosis Ended

2024-519335-42-01 Systemic Sclerosis 4 2025-12-22
A study to investigate the efficacy and safety of subcutaneous sonelokimab versus placebo in participants aged 18 years and over with active… Ended

2024-516213-20-00 Psoriatic arthritis 5 2025-03-25
RCT of Medical Cannabis Aerosol for DPNP Treatment Ended

2023-508932-68-00 Diabetic Peripheral Neuropathic Pain 4 2024-11-14
A study to find how well Dazodalibep works and how safe it is in participants with Sjögren’s Syndrome Ended

2023-503923-24-00 Sjögren’s Syndrome With Moderate-toSevere Symptom State 5 2024-07-22
A Phase 3 Randomized, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of MK-0616 in Reducing Major Adverse Cardiovascu… Ended

2022-502781-24-01 ASCVD - Atherosclerotic Cardiovascular Disease 5 2024-06-05
A study to assess adverse events and effectiveness of upadacitinib oral tablets in adult and adolescent participants with vitiligo. Ended

2023-506195-27-00 non-segmental vitiligo 5 2024-04-05
Efficacy and Safety of Deucravacitinib Compared with Placebo in Participants with Active Psoriatic Arthritis (PsA) who are Naïve to Biologic… Ended

2023-506256-25-00 Active Psoriatic Arthritis 5 2021-10-20
Guselkumab versus Placebo for the Treatment of Active Psoriatic Arthritis in Participants with Inadequate Response and/or Intolerance to One… Ended

2023-504715-33-00 Psoriatic Arthritis 5 2021-09-27
A Study Comparing Risankizumab to Placebo in Subjects with Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Respo… Ended

2023-505477-33-00 Psoriatic Arthritis 5 2019-06-18
A Study Comparing Risankizumab to Placebo in Subjects with Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or … Ended

2023-505478-14-00 Psoriatic Arthritis 5 2019-05-09
A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Crohn's Disease who Comple… Ended

2023-504951-29-00 Chron's Disease 5 2017-07-27
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Subjects with Rheumatoid Arthritis who are on a Stable Dose of Meth… Ended

2022-501017-31-00 Rheumatoid arthritis 5 2016-05-10
A randomised, double-blind, multicentre study comparing the efficacy, safety and immunogenicity of proposed Abatacept biosimilar (DRL_AB) wi… Ended

2023-506664-14-00 Rheumatoid Arthritis 5 2024-10-24